Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Common Equity: 2015-2024

Historic Common Equity for Wave Life Sciences (WVE) over the last 10 years, with Dec 2024 value amounting to $209.5 million.

  • Wave Life Sciences' Common Equity fell 12.07% to $124.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.5 million, marking a year-over-year decrease of 12.07%. This contributed to the annual value of $209.5 million for FY2024, which is 428.68% up from last year.
  • Latest data reveals that Wave Life Sciences reported Common Equity of $209.5 million as of FY2024, which was up 428.68% from $39.6 million recorded in FY2023.
  • Wave Life Sciences' Common Equity's 5-year high stood at $209.5 million during FY2024, with a 5-year trough of -$45.1 million in FY2022.
  • Its 3-year average for Common Equity is $68.0 million, with a median of $39.6 million in 2023.
  • As far as peak fluctuations go, Wave Life Sciences' Common Equity crashed by 238.75% in 2022, and later skyrocketed by 428.68% in 2024.
  • Wave Life Sciences' Common Equity (Yearly) stood at $82.8 million in 2020, then crashed by 60.74% to $32.5 million in 2021, then plummeted by 238.75% to -$45.1 million in 2022, then skyrocketed by 187.89% to $39.6 million in 2023, then surged by 428.68% to $209.5 million in 2024.